Takeda Pharmaceutical Co., Ltd (NYSE:TAK) on Thursday announced positive topline results for the two pivotal Phase 3 studies of zasocitinib (TAK-279) for moderate-to-severe plaque psoriasis (PsO).

Data

The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24.

The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100, and sPGA 0 against placebo and Amgen Inc.’s (NASDAQ:AMGN) Otezla (apremilast), showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO.

Also Read: FDA Flags Antibody Risk After Child’s Death Linked To Takeda’s Enzyme Replacement Therapy For Rare Blood Disorder

Zasocitinib was ...